Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40
Chardan Capital has reiterated its Buy rating for Alumis (ALMS.US) and increased its target price to $40. This revision suggests a strong outlook from the firm regarding Alumis's future performance.
ALMS Maintained by Chardan Capital -- Price Target Raised to $40
Chardan Capital analyst Janani Sundararajan has reaffirmed a 'Buy' rating for Alumis (ALMS) and increased the price target to $40.00 from $38.00, reflecting confidence in the company's growth potential despite its low GF Score™ of 14/100. Alumis, a clinical-stage biopharmaceutical company with a market cap of $2.70 billion, focuses on developing innovative therapies, particularly two Tyrosine Kinase 2 (TYK2) inhibitors. While the stock's current price of $21.15 suggests potential upside based on analyst expectations, investors are advised to consider the company's low profitability rank and overall financial health.
Alumis price target raised to $40 from $38 at Chardan
Chardan has increased its price target for Alumis (ALMS) to $40 from $38, maintaining a Buy rating on the shares. This adjustment reflects updated pricing assumptions for envudeucitinib, minor changes in psoriasis penetration, and revised financial data following the company's first-quarter results and business update. Other analysts from Morgan Stanley, Wells Fargo, and Guggenheim also raised their price targets for Alumis, while H.C. Wainwright downgraded the stock to Neutral.
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones
Alumis (ALMS) stock is under scrutiny after reporting positive Phase 3 data for its oral TYK2 inhibitor envudeucitinib but also weaker Q1 2026 revenue. Despite recent short-term pullbacks, the stock has shown strong long-term momentum. The article questions whether Alumis is undervalued after the recent data or if its future growth is already priced in, noting its P/B ratio of 5.1x suggests it is overvalued compared to industry averages and peers.
[ARS] ALUMIS INC. SEC Filing
This article reports on an ARS SEC filing by Alumis Inc. (ALMS) on May 18, 2026, at 04:29 PM. The filing is categorized with low impact and neutral sentiment. The article also provides recent news and SEC filings related to Alumis Inc., along with key stock data.
[DEF 14A] ALUMIS INC. Definitive Proxy Statement
Alumis Inc. has filed a Definitive Proxy Statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on June 30, 2026. Stockholders are asked to elect three Class II directors and ratify the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. The document details board composition, governance policies, executive and director compensation, and related person transactions, with a record date of May 5, 2026, for voting eligibility.
Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026
Cormorant Asset Management has acquired 313,645 shares of Alumis during Q1 2026, investing $7.84 million in the biotechnology company. This investment increased Cormorant's stake value in Alumis by $51.52 million and represents 4.37% of its 13F assets. Alumis shares have surged 400% over the past year, driven by strong clinical trial data for its autoimmune and neuroinflammatory disorder therapies, with a New Drug Application expected in Q4 2026.
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors?
Alumis Inc. (ALMS) reported Q1 2026 results with a net loss of US$93.05 million, but highlighted strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis. The company plans a New Drug Application in late 2026 for envudeucitinib and anticipates pivotal systemic lupus erythematosus data in Q3 2026, positioning the drug as a central asset. Investors are encouraged to focus on envudeucitinib's potential as a platform asset rather than current financials, with planned milestones expected to reshape the company's risk and reward profile.
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors?
Alumis Inc. reported Q1 2026 losses and declining revenue, despite strong Phase 3 data for its oral TYK2 inhibitor, envudeucitinib. The company plans a New Drug Application for envudeucitinib in late 2026 for psoriasis and anticipates data for systemic lupus erythematosus, making this drug central to its strategy. Investors need to evaluate if they believe in envudeucitinib as a platform asset, considering the company's current financial losses and the concentration of risk in this single program.
Alumis (Nasdaq:ALMS) - Aktienanalyse
Alumis Inc. (Nasdaq:ALMS) is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for autoimmune diseases. The company's stock is currently trading at US$22.04, with analysts estimating a fair value of US$40.1, indicating it is undervalued. Recent news highlights positive Phase 3 data for its psoriasis drug envudeucitinib, with plans for an NDA submission in Q4 2026, and potential pivotal Phase 2b data for systemic lupus erythematosus in Q3 2026.
HC Wainwright & Co. downgrades Alumis (ALMS)
This article reports that HC Wainwright & Co. has downgraded its rating for Alumis (ALMS). The specific details or reasons for the downgrade are not provided within the given content.
Stifel reiterates Alumis stock rating on psoriasis trial data
Stifel maintained a Buy rating and a $44.00 price target for Alumis Inc (ALMS) after the company's first-quarter 2026 update and positive Phase 3 data for its TYK2 inhibitor, envudeucitinib, in psoriasis. The firm highlighted that the data for envudeucitinib were comparable to or better than competitor drugs, and anticipates the upcoming Phase 2b data in systemic lupus erythematosus in Q3 2026 as a key catalyst. Other analysts from Guggenheim, H.C. Wainwright, Raymond James, and Leerink Partners also reiterated positive ratings based on the strong clinical trial results.
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
This article details the top five analyst downgrades on Friday, May 15, 2026. Alumis Inc. (NASDAQ: ALMS) saw its rating cut from Buy to Neutral, while Tango Therapeutics (NASDAQ: TNGX), Viking Holdings (NYSE: VIK), Aardvark Therapeutics (NASDAQ: AARD), and A.O. Smith Corp (NYSE: AOS) also received downgrades from various analysts. The article provides the new ratings, price targets, and closing prices for each mentioned stock.
Guggenheim raises Alumis stock price target to $34 on psoriasis data
Guggenheim has increased its price target for Alumis Inc (NASDAQ:ALMS) to $34 from $32 and maintained a Buy rating, following positive first-quarter earnings and promising clinical trial updates for its oral TYK2 inhibitor, envudeucitinib, in psoriasis. The company's stock has seen significant growth, and it holds a strong financial position with cash funding operations into late 2027. Alumis is also advancing other clinical programs, including a systemic lupus erythematosus trial and plans for additional TYK2 inhibitor indications.
Alumis psoriasis pill hits 68% PASI 90 in Phase 3 trial
Alumis (NASDAQ: ALMS) reported its Q1 2026 financial results, including a net loss of $93.1 million and cash reserves of $569.5 million, which are expected to fund operations into Q4 2027. The company highlighted strong Phase 3 clinical data for its psoriasis treatment, envudeucitinib, showing PASI 90 responses of 68.0% and 62.1%, and anticipates filing a New Drug Application (NDA) in Q4 2026. Additionally, Alumis expects pivotal Phase 2b data for envudeucitinib in Systemic Lupus Erythematosus (SLE) in Q3 2026 and is exploring strategic alternatives for its lonigutamab program.
Press Release: Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
The press release from Alumis reports the company's financial results for the first quarter of 2026 and highlights recent achievements. Additionally, it mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million and a quarterly loss of 66 cents per share. The article also provides a disclaimer regarding the informational nature of the content and investment risks.
Envudeucitinib Phase 3 gains and Q1 2026 results for Alumis (NASDAQ: ALMS)
Alumis Inc. reported its Q1 2026 financial results, showing a net loss of $93.053 million despite lower revenue compared to the previous year. The company also highlighted strong Phase 3 data for its oral TYK2 inhibitor, envudeucitinib, for moderate-to-severe plaque psoriasis, with plans for an NDA submission in Q4 2026 and anticipated pivotal Phase 2b data for systemic lupus erythematosus in Q3 2026. Alumis ended the quarter with $569.5 million in cash, cash equivalents, and marketable securities, projecting this will fund operations into Q4 2027.
Earnings Flash (ALMS) Alumis Inc. Reports Q1 Revenue $1.7M, vs. FactSet Est of $2.5M
Alumis Inc. (ALMS) reported Q1 revenue of $1.7 million, falling short of the FactSet estimate of $2.5 million. The company, a late-stage biopharmaceutical firm, is focused on developing targeted therapies for immune-mediated diseases, including oral TYK2 inhibitors and a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy.
ALUMIS INC. to present new biomarker data on investigational PsO treatment at Chicago conference
ALUMIS INC. is scheduled to present new biomarker data for envudeucitinib, an investigational oral treatment for psoriasis (PsO), at the SIDChicago26 conference on May 14. This presentation will occur during a poster session, providing the latest research insights into the potential of envudeucitinib. The company encourages attendees to explore their ongoing clinical work at the event.
Number of shareholders of Alumis Inc. – NASDAQ:ALMS
This article focuses on the number of shareholders for Alumis Inc. (NASDAQ: ALMS). It provides a brief overview of the company's stock information, including its market status and a section for financial data related to shareholder numbers, period value, and change percentages.
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $49
Wells Fargo has reiterated its "Buy" rating for Alumis (ALMS.US) and increased its target price to $49 from the previous $45. This adjustment follows the release of positive top-line clinical trial results for ESK-001, which the analysts believe de-risks the drug's short-term prospects and strengthens Alumis's position in the immunology market.
Alumis Inc: Year-End 2025 Financial Results and Strategic TYK2 Pipeline Outlook
Alumis Inc., a biopharmaceutical company, reported its financial results for the full year 2025, highlighting significant clinical validation of its lead asset, envudeucitinib, and a robust cash position following a major capital raise. The company recorded $24.05 million in revenue and narrowed its net loss to $243.33 million. Alumis plans to submit a New Drug Application for psoriasis in late 2026 and expects further clinical milestones in its pipeline.
ALMS Price Today: Alumis Inc. Stock Price, Quote & Chart | MEXC
Alumis Inc. (ALMS) is currently trading at $24.93 on NASDAQ, showing a 0.00% change today but significant returns of +23.35% over the past month and +505.10% over the last year. The company, classified in the PHARMACEUTICAL PREPARATIONS sector, has a market capitalization of $3.07 billion and focuses on developing TYK2 inhibitors for various diseases. Investors can buy and trade ALMS on MEXC.
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Alumis Inc. (NASDAQ:ALMS) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $38.60. Despite mostly bullish analyst sentiment, with several firms raising price targets and ratings, the company recently missed quarterly EPS and revenue estimates, showing weak fundamentals. Institutional investors have been increasing their positions in the biopharmaceutical company.
Saturn V Capital Management LP's Alumis Inc(ALMS) Holding History
This article details Saturn V Capital Management LP's holdings in Alumis Inc (ALMS). As of December 31, 2025, the firm held 3.14 million shares valued at $30.61 million, representing 5.62% of their portfolio. The initial purchase was in Q4 2025 at an average price of $7.03 per share, resulting in an estimated gain of $56.35 million or 255.62% to date.
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 25.3% in March
Alumis Inc. (NASDAQ:ALMS) saw a significant increase in short interest by 25.3% in March, reaching 11,230,693 shares, which represents 14.9% of its total shares sold short. Despite this, analysts largely maintain a "Moderate Buy" rating with an average price target of $38.60, and several firms have raised their price objectives. Institutional investors have also increased their positions in the company, even as Alumis missed recent revenue and EPS estimates.
H.C. Wainwright reiterates Alumis stock rating, $25 target
H.C. Wainwright has reiterated a Buy rating and a $25 price target for Alumis Inc. (NASDAQ: ALMS) following details from an Inflammatory Skin Disease Conference regarding its "envu" product, which H.C. Wainwright considers a strong oral TYK2 inhibitor. The company's stock has surged 372% in six months, demonstrating a strong market response. Other analysts from firms like Raymond James and Leerink Partners also maintain positive ratings, citing promising Phase 3 trial data for envudeucitinib in treating plaque psoriasis.
H.C. Wainwright reiterates Alumis stock rating, $25 target
H.C. Wainwright reiterated a Buy rating and a $25 price target for Alumis Inc. (NASDAQ:ALMS), highlighting its envu product as a potentially strong oral TYK2 inhibitor. This assessment followed an Inflammatory Skin Disease Conference and comes after other analysts also maintained positive ratings on Alumis due to promising Phase 3 trial data for its drug envudeucitinib in treating psoriasis. The stock has seen a significant surge recently and is currently trading above its Fair Value.
H.C. Wainwright Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright has reiterated its Buy rating for Alumis (ALMS.US) and maintained a target price of $25. This indicates continued confidence from the analyst firm in the company's prospects.
H.C. Wainwright reiterates Alumis stock rating, $25 target By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $25 price target for Alumis Inc. (NASDAQ:ALMS) following an Inflammatory Skin Disease Conference. The firm highlighted Alumis's envu product as a potentially strong oral TYK2 inhibitor, with patient response expected to deepen beyond 24 weeks. This analyst confidence is further supported by recent Phase 3 trial data showing promising results for envudeucitinib in treating plaque psoriasis, leading multiple other firms to also maintain positive ratings and price targets for the stock.
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT
Morgan Stanley has resumed coverage of Alumis (ALMS) stock, setting a price target of $23. This indicates a positive outlook from the investment bank for the biopharmaceutical company.
Alumis Inc. $ALMS Shares Sold by Trium Capital LLP
Trium Capital LLP significantly reduced its stake in Alumis Inc. (NASDAQ:ALMS) by 71.4% in the fourth quarter, selling over 2.2 million shares but still retaining roughly 0.86% of the company. Despite this large sale, analysts have a "Moderate Buy" rating with a consensus price target of $38.60 for Alumis. Operationally, Alumis missed quarterly earnings and revenue expectations and shows significant negative profitability.
How Investors Are Reacting To Alumis (ALMS) Psoriasis Drug’s Strong Phase 3 Data And Safety Profile
Alumis Inc. (ALMS) has reported positive Phase 3 data for its oral TYK2 inhibitor, envudeucitinib, showing high rates of skin clearance and quality-of-life improvements for psoriasis patients with a good safety profile. This strong data reinforces the drug's potential as a core value driver for the company, although investors should also consider the ongoing funding needs and dilution risks, as Alumis is still pre-profit. The next catalysts include a planned psoriasis NDA filing in H2 2026 and upcoming lupus data.
How Investors Are Reacting To Alumis (ALMS) Psoriasis Drug’s Strong Phase 3 Data And Safety Profile
Alumis Inc. recently released strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib, showing robust and durable skin clearance for psoriasis patients with a good safety profile. While this data strengthens the investment case for envudeucitinib as a core value driver, the company faces ongoing dilution and funding risks due to its net loss and recent equity raises. Investors are advised to consider these factors alongside the promising drug trial results.
ALUMIS INC. unveils psoriasis treatment isolating effects to immune cells only
ALUMIS INC. has revealed new Phase 3 data for its TYK2 inhibitor, an oral treatment for psoriasis. This innovative approach targets specific immune cells responsible for the condition, aiming to reduce skin inflammation with fewer side effects and less unwanted immunosuppression. The company held an investor webcast on March 29 to discuss these findings further.
Deep Track files Schedule 13G reporting 7.36M shares in ALMS (ALMS)
Deep Track Capital, Deep Track Biotechnology Master Fund, and David Kroin have jointly filed a Schedule 13G, reporting beneficial ownership of 7,362,035 shares of ALUMIS Inc. (ALMS). This represents 5.98% of the company's common stock as of April 7, 2026. The filing indicates shared voting and dispositive power over these shares, based on 123,139,425 shares outstanding as of March 12, 2026.
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Psoriasis Results And NDA Plans
Alumis Inc. (ALMS) is gaining significant attention following positive Phase 3 data for its drug envudeucitinib in treating moderate to severe plaque psoriasis, along with plans for a U.S. FDA New Drug Application. The company's stock has seen substantial growth over the past year, currently valued at approximately US$3.0 billion. Despite trading at a higher Price-to-Book multiple (9.9x) compared to the broader US pharmaceuticals industry, this valuation reflects investor confidence in its pipeline, especially when compared to a focused peer set.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are showing bullish sentiment towards Alumis Inc. (ALMS) and PepGen Inc. (PEPG) within the Healthcare sector. Stifel Nicolaus maintained a Buy rating for Alumis with a $44.00 price target, while analysts give it a "Strong Buy" consensus. PepGen also received a maintained Buy rating from Stifel Nicolaus with a $12.00 price target, and a "Moderate Buy" consensus from analysts.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts show bullish sentiment for two healthcare companies, Alumis Inc. (ALMS) and PepGen Inc. (PEPG). Alumis Inc. received a "Strong Buy" consensus with a significant upside, while PepGen Inc. was rated "Moderate Buy" with an even higher potential upside from current levels. Analysts from Stifel Nicolaus and Chardan Capital reaffirmed their Buy ratings and price targets for both companies.
10 Best Performing Stocks of Q1 2026 to Watch for Q2
This article highlights Alumis Inc. (NASDAQ:ALMS) as one of the best-performing stocks of Q1 2026, with a 145.87% performance. Raymond James and Guggenheim both reiterated "Buy" ratings following positive Phase 3 trial data for its drug "envu" for plaque psoriasis, which showed a strong safety profile advantage over a competitor. The article, which is part of a larger list, also suggests that while ALMS has potential, certain AI stocks might offer greater returns and less downside risk.
10 Best Performing Stocks of Q1 2026 to Watch for Q2
This article highlights Alumis Inc. (NASDAQ:ALMS) as one of the top-performing stocks of Q1 2026, with a 145.87% performance. Raymond James and Guggenheim both reiterated "Strong Buy" and "Buy" ratings, respectively, following positive Phase 3 trial data for its plaque psoriasis drug, envu, which showed a strong safety profile compared to a competitor. The article, however, suggests that some AI stocks might offer greater return potential and lower downside risk than ALMS.
ALMS SEC Filings - Alumis Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Alumis Inc. (ALMS) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It offers AI-generated summaries and key-point extractions for regulatory disclosures, helping investors understand financial results, merger-related information, and clinical program updates. The platform tracks 57 SEC filings for Alumis, with the most recent one filed on August 1, 2025.
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions
Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC reported Form 4 transactions for ALUMIS (ALMS) common stock on April 1, 2026. These transactions, coded "J," represent pro rata, in-kind distributions among affiliated Foresite entities and are not market purchases or sales. The filings clarify that these internal transfers occurred without additional consideration, falling under Exchange Act exemptions 16a-13 and 16a-9, and involved a total of 4,103,630 shares.
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions
Alumis (ALMS) director and 10% owner James B. Tananbaum reported an internal restructuring of 4,103,630 shares of common stock. These were "J" transactions, meaning pro rata, in-kind distributions among affiliated entities (Foresite and Labs-related funds and LLCs) for no consideration, not open-market purchases or sales. Tananbaum disclaims beneficial ownership beyond his pecuniary interest and group status.
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans
Alumis Inc. reported positive Phase 3 results for envudeucitinib in psoriasis, leading to plans for an FDA New Drug Application in mid-2026. Despite the strong clinical data and potential for envudeucitinib to anchor Alumis' immunology pipeline, the stock saw a decline, possibly due to over-optimistic valuation and existing risks such as the company being loss-making and relying on equity issuance. The situation highlights a tension between scientific strengthening and heightened investor expectations.
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans
Alumis Inc. recently announced positive Phase 3 results for envudeucitinib in moderate-to-severe plaque psoriasis, demonstrating strong skin clearance and safety. Despite these positive results and plans for a New Drug Application filing in late 2026, the company's stock, ALMS, is down 8.4%. The article explores how this data and the planned FDA submission impact Alumis' investment narrative, highlighting both opportunities and risks, such as the company's loss-making status and reliance on equity issuance.
Why Alumis Inc. Shares Are Suddenly Surging
Alumis Inc. (ALMS) shares are experiencing a significant surge due to strong Phase 3 data for its oral psoriasis drug, envudeucitinib, which demonstrated competitive efficacy and a superior safety profile. This positive news, coupled with notable insider buying and growing optimism for a 2026 regulatory submission, has led analysts like Oppenheimer to raise price targets and reiterate "outperform" ratings. The stock's year-to-date performance is up 125.72%, with a current market cap of $2.8 billion.
Why Alumis Inc. Shares Are Suddenly Surging
Alumis Inc. (ALMS) shares surged after the company unveiled strong Phase 3 results for its oral psoriasis drug, envudeucitinib, at the 2026 American Academy of Dermatology Annual Meeting. The positive trial data, showing solid skin clearance and symptom relief, has led to increased investor enthusiasm and analysts raising their price targets, including Oppenheimer setting a new target of $55. This clinical success is reshaping Wall Street's outlook on the stock, with the company planning to file for U.S. approval later this year.
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade
Alumis (NASDAQ:ALMS) shares surged 12.1% after Oppenheimer raised its price target from $50 to $55, maintaining an outperform rating. Insider buying also contributed to positive sentiment, with significant purchases reported by Foresite Capital and director James B. Tananbaum. Despite mixed analyst sentiment and weak fundamentals, the average rating remains a "Moderate Buy" with an average target price of $38.60.
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST)
Analysts have expressed bullish sentiment towards healthcare stocks Alumis Inc. (ALMS) and Aquestive Therapeutics (AQST). Chardan Capital and Morgan Stanley maintained Buy ratings for Alumis Inc., with price targets around $38, representing a significant upside. Lake Street also maintained a Buy rating for Aquestive Therapeutics, setting a price target of $6.00, contributing to a Strong Buy consensus for both companies.
